Hepatitis C and recurrent treatment-resistant acute ischemic stroke.

Proc (Bayl Univ Med Cent)

Department of Neurology (Saxsena, Tarsia, Dunn, Aysenne) and Department of Radiology (Shah), Tulane University Medical Center, New Orleans, Louisiana; and the Baylor Neuroscience Center, Baylor University Medical Center at Dallas (Moore).

Published: April 2013

Since the introduction of recombinant tissue plasminogen activator and thrombolysis, acute ischemic stroke has become a treatable disorder if the patient presents within the 4.5-hour time window. Typically, sporadic stroke is caused by atherosclerotic disease involving large or small cerebral arteries or secondary to a cardioembolic source often associated with atrial fibrillation. In the over-65-year age group, more rare causes of stroke, such as antiphospholipid syndromes, are unusual; such stroke etiologies are mostly seen in a younger age group (<55 years). Here we describe acute ischemic stroke in three patients >65 years with hepatitis C-associated antiphospholipid antibodies. We suggest that screening for antiphospholipid disorders in the older patient might be warranted, with potential implications for therapeutic management and secondary stroke prevention.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603743PMC
http://dx.doi.org/10.1080/08998280.2013.11928955DOI Listing

Publication Analysis

Top Keywords

acute ischemic
8
ischemic stroke
8
age group
8
stroke
6
hepatitis recurrent
4
recurrent treatment-resistant
4
treatment-resistant acute
4
stroke introduction
4
introduction recombinant
4
recombinant tissue
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!